$AVBP

ArriVent BioPharma, Inc.

ArriVent BioPharma is a clinical-stage biopharmaceutical company developing medicines for patients with cancer, initially focusing on solid tumors. Its lead candidate, firmonertinib, is an investigational EGFR tyrosine kinase inhibitor being studied in non-small cell lung cancer with uncommon EGFR mutations, including exon 20 insertion and PACC mutations. The company is conducting Phase 3 trials of firmonertinib and holds rights to develop and commercialize it worldwide except greater China. ArriVent also develops antibody drug conjugates. Its pipeline includes ARR-217, a CDH17-targeting candidate for gastrointestinal cancers that is in Phase 1 clinical development, and preclinical candidate ARR-002. It works with partners on ADC discovery and development, and has licensed or collaborated on oncology programs. The company’s business centers on developing and commercializing drug candidates and securing rights to therapeutic assets through licensing and collaborations. ArriVent is headquartered in Newtown Square, Pennsylvania.

0
0
1

No SEC Form 4 filings for $AVBP in the last 30 days.

See all $AVBP insider activity →
Low

Guggenheim lowers ArriVent BioPharma stock price target to $28

Guggenheim cut its price target on ArriVent BioPharma (AVBP) to $28 from $30, keeping a Buy rating. The stock is down 53% in six months, trading at $13.01. The firm adjusted estimates after Q3 2026 results, including a Phase 3 miss for FURVENT. ArriVent has $393.2M in cash, expected to last until mid-2028. Analysts have mixed views on its prospects.

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

AVBP sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning AVBP (ArriVent BioPharma, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent AVBP coverage spans financial news, earnings and corporate actions.

What's driving AVBP

  • Target cut suggests weaker outlook, likely prompting sell pressure.

    investing.com · Nov 16, 2026

  • Truist Securities maintained its Buy rating on ArriVent BioPharma and increased its price target to $24 from $21, representing a 14.3% increase. This new target suggests a 69.5% upside from the stock's Nov 9 close of $14.16. Other recent analyst price targets for the company range from $29 to $30.

    tradingview.com · Nov 10, 2026

  • The miss on the FURVENT primary endpoint and modest ALPACCA data likely weigh on the stock.

    rttnews.com · Nov 10, 2026

  • The company posted a modest revenue boost but a larger loss, suggesting short‑term pressure on the stock.

    tradingview.com · Nov 9, 2026

  • Executive turnover in R&D may raise uncertainty about pipeline progress, potentially weighing on the stock.

    tradingview.com · Nov 9, 2026

AlphAI scores every news story that mentions AVBP with an AI model for sentiment and relevance, and aggregates insider trades from ArriVent BioPharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AVBP

Score
$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

$AVBPMedEarnings

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

$AVBPMedAI 8/10

Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

$AVBPMedAI 9/10Clinical / regulatory· topline data

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 · 44.8% ORR at 6mg/kg dose in late-line CRC patients · ARR-217 was generally well-tolerated · ArriVent to host virtual webinar on Mo

Related tickers